Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality

被引:50
作者
Greiman, Alyssa K. [1 ]
Rosoff, James S. [2 ]
Prasad, Sandip M. [1 ,3 ]
机构
[1] Med Univ South Carolina, Dept Urol, CSB 644,96 Jonathan Lucas St, Charleston, SC 29425 USA
[2] Yale Sch Med, Dept Urol, New Haven, CT USA
[3] Ralph M Johnson VA Med Ctr, Dept Surg, Charleston, SC USA
关键词
bladder cancer; kidney cancer; prostate cancer; testis cancer; epidemiology;
D O I
10.1111/bju.13875
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo describe contemporary worldwide age-standardized incidence and mortality rates for bladder, kidney, prostate and testis cancer and their association with development. Materials and MethodsWe obtained gender-specific, age-standardized incidence and mortality rates for 184 countries and 16 major world regions from the GLOBOCAN 2012 database. We compared the mortality-to-incidence ratios (MIRs) at national and regional levels in males and females, and assessed the association with socio-economic development using the 2014 United Nations Human Development Index (HDI). ResultsAge-standardized incidence rates were 2.9 (bladder) to 7.4 (testis) times higher for genitourinary malignancies in more developed countries compared with less developed countries. Age-standardized mortality rates were 1.5-2.2 times higher in more vs less developed countries for prostate, bladder and kidney cancer, with no variation in mortality rates observed in testis cancer. There was a strong inverse relationship between HDI and MIR in testis (regression coefficient 1.65, R-2 = 0.78), prostate (regression coefficient -1.56, R-2 = 0.85), kidney (regression coefficient -1.34, R-2 = 0.74), and bladder cancer (regression coefficient -1.01, R-2 = 0.80). ConclusionWhile incidence and mortality rates for genitourinary cancers vary widely throughout the world, the MIR is highest in less developed countries for all four major genitourinary malignancies. Further research is needed to understand whether differences in comorbidities, exposures, time to diagnosis, access to healthcare, diagnostic techniques or treatment options explain the observed inequalities in genitourinary cancer outcomes.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 62 条
  • [1] Ferlay J., Soerjomataram I., Ervik M., Et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], (2013)
  • [2] Access to cancer treatment. A study of medicine pricing issues with recommendations for improving access to cancer medicine. A report prepared for OXFAM [Internet]
  • [3] Pakzad H., Mohammadian-Hafshejani A., Ghoncheh M., Et al., The Incidence and mortality of prostate cancer and its relationship with development in Asia, Prostate Int, 3, pp. 135-140, (2015)
  • [4] Jeffreys M., Sarfati D., Stevanovic V., Et al., Socioeconomic inequalities in cancer survival in New Zealand: The role of extent of disease at diagnosis, Cancer Epidemiol Biomarkers Prev, 18, pp. 915-921, (2009)
  • [5] Torre L.A., Bray F., Siegel R.L., Et al., Global cancer statistics, 2012, CA Cancer J Clin, 65, pp. 87-108, (2015)
  • [6] Forman D., Bray F., Brewster D.H., Et al., Cancer Incidence in Five Continents, Vol. X (electronic version)
  • [7] Ferlay J., Soejomataram I., Dikshit R., Et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, pp. E359-E386, (2014)
  • [8] Parkin D., Ferlay J., Curado M.P., Et al., Cancer incidence in five continents, Int J Cancer, 127, pp. 2918-2927, (2010)
  • [9] Hebert J., Daguise V., Hurley D., Et al., Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population, Cancer, 115, pp. 2539-2552, (2009)
  • [10] Asadzadeh Vostakolaei F., Karim-Kos H., Janssen-Heijnen M., Et al., The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival, Eur J Public Health, 21, pp. 573-577, (2010)